You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Kronos is working with Tempus to sequence patients' tumor samples in the study for MYC amplification and overexpression.
The Phase II trial will use OmniSeq's RNA-seq assay to determine whether patients should be treated with one of two agents combined with BMS' nivolumab.
Sema4 will use its next-generation sequencing testing services to identify patients with solid tumors harboring NRG1 fusions for Merus' Phase I/II drug trial.
The Jerusalem-based drug developer is studying PLX8394 in patients with BRAF V600-mutated gliomas and solid tumors with non-V600 mutations.
The partnership goes hand-in-hand with Genentech's new precision basket trial, for which it will identify and enroll patients across OneOncology's network.
Using RNA and DNA sequencing to predict tumor site and detect gene alterations may allow patients with CUP to receive appropriate targeted treatment.
The randomized, Phase II trial will test ctDNA-guided second-line adjuvant therapy for stage II and III hormone receptor-positive, HER-2 negative breast cancer.
The trial will use Natera's Signatera test to determine patient enrollment eligibility based on the presence of ctDNA and to evaluate response based on ctDNA clearance.
Strata will use its StrataNGS profiling test to identify patients with advanced solid tumors harboring KRAS G12C mutations for enrollment into Mirati's KRYSTAL-1 trial.
Caris will use its suite of technologies to help Elevation Oncology enroll patients with NRG1 fusion-positive solid tumors to its Phase II trial of seribantumab.
Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.
Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.
Science reports that a Dutch research funding agency is combating a ransomware attack.
In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.